FDA Asked to Seek Benefits-Risk Assessment Data from Abortion Pill Makers
Pensacola, FL (June 25, 2025)—FDA Commissioner Marty Makary has recently promised to undertake a new review of the “postmarketing safety data on mifepristone for the medical termination of early pregnancy.” In an open letter to the Commissioner, Elliot Institute director David Reardon, has asked Makary to also direct the FDA to require the abortion pill […]